TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases

Tengfei Xiao; Mingzhong Sun; Chuanxiang Zhao; Jingjing Kang

doi:10.3389/fphar.2023.1037925

TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases

Front Pharmacol. 2023 Feb 15:14:1037925. doi: 10.3389/fphar.2023.1037925. eCollection 2023.

Authors

Tengfei Xiao¹, Mingzhong Sun¹, Chuanxiang Zhao², Jingjing Kang³

Affiliations

¹ Department of Clinical Laboratory, The Sixth Affiliated Hospital of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
² Institute of Medical Genetics and Reproductive Immunity, School of Medical Science and Laboratory Medicine, Jiangsu College of Nursing, Huai'an, Jiangsu, China.
³ Department of Clinical Laboratory, Affiliated Hospital of Nanjing University Medical School, Yancheng First People's Hospital, Yancheng, Jiangsu, China.

Abstract

TRPV1 is a non-selective channel receptor widely expressed in skin tissues, including keratinocytes, peripheral sensory nerve fibers and immune cells. It is activated by a variety of exogenous or endogenous inflammatory mediators, triggering neuropeptide release and neurogenic inflammatory response. Previous studies have shown that TRPV1 is closely related to the occurrence and/or development of skin aging and various chronic inflammatory skin diseases, such as psoriasis, atopic dermatitis, rosacea, herpes zoster, allergic contact dermatitis and prurigo nodularis. This review summarizes the structure of the TRPV1 channel and discusses the expression of TRPV1 in the skin as well as its role of TRPV1 in skin aging and inflammatory skin diseases.

Keywords: Ca 2+; TRPV1; inflammatory skin diseases; skin aging; therapeutic strategy.

Publication types

Review

Grants and funding

This research was funded by the Huai’an Natural Science Research Program (Grant No. HABL202114), Huai’an “Tianyixing” key Laboratory of Medical Examination (Grant No. HAP202004), the Science and Technology Development Project of Yancheng, China (YK2019108) and the Nantong University Clinical Medicine Special Project, China (2019JZ011).